Vyome Holdings, Inc
HINDNasdaq
$2.15
↓ -1.8%Jul 17 close · end-of-day
Price
1Y↓ -81.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$14.4M
Enterprise Value
$5.6M
P/E
0.0
P/S
94.2
P/B
1.8
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$152,724.00
Net Income (TTM)
-$10.9M
Free Cash Flow (TTM)
—
Gross Margin
53.0%
Operating Margin
-7453.7%
Net Margin
-7157.3%
ROE
-135.9%
ROIC
—
Debt / Equity
—
Net Cash
$8.8M
Return 1Y
-81.1%
Company profile
ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. Its product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes.
- CEO
- Paul F. Hickey
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 50
- Headquarters
- California
- Website
- reshapelifesciences.com
Management & directors
- Dickey Robert IvChief Financial Officer
- Nelabhotla VenkateswarluPresident and CEO
Roles derived from SEC Form 4 filings.
Earnings
HIND Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$31,591.00↓ -84.1%
Diluted EPS-$0.15↓ -100.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $11.3M | $13.6M | $11.2M | $8.7M | $256,944.00 | $319,714.00 |
| Gross profit | $6.3M | $8.3M | $6.8M | $5.5M | $194,970.00 | $218,771.00 |
| Operating income | -$12.5M | -$57.9M | -$46.4M | -$15.4M | -$1.0M | -$10.5M |
| Net income | -$21.6M | -$63.1M | -$46.2M | -$11.4M | -$1.4M | -$10.3M |
| Diluted EPS | -$5.55 | -$288.97 | -$108.90 | -$110.87 | -$6,001.39 | -$4.86 |
| Operating cash flow | -$8.6M | -$15.4M | -$21.9M | -$17.0M | -$614,136.00 | -$3.7M |
| Free cash flow | -$8.7M | — | — | — | — | — |
| Gross margin | 55.4% | 61.4% | 60.5% | 63.9% | 75.9% | 68.4% |
| Operating margin | -110.2% | -425.6% | -412.4% | -177.3% | -391.7% | -3269.4% |
| Net margin | -191.4% | -464.3% | -411.2% | -131.2% | -563.3% | -3209.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $84,526.00 | -$3.7M | $198,581.00 | $1.2M | $34,627.00 | -$1.2M | $31,591.00 |
| Gross profit | $1.1M | $37,085.00 | -$2.1M | $154,419.00 | $599,000.00 | $18,050.00 | -$552,698.00 | $16,645.00 |
| Operating income | -$2.1M | -$280,978.00 | $3.5M | -$198,998.00 | -$2.8M | -$8.6M | $1.1M | -$1.1M |
| Net income | -$1.6M | -$547,772.00 | $2.9M | -$293,974.00 | -$2.6M | -$8.4M | $1.1M | -$962,910.00 |
| Diluted EPS | -$91.56 | -$1,419.10 | -$4,355.36 | -$761.59 | -$2.25 | -$3.12 | $762.10 | -$0.15 |
| Operating cash flow | $1.8M | -$374,117.00 | -$2,968.00 | -$203,533.00 | -$297,003.00 | -$1.8M | -$1.5M | -$1.4M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 57.7% | 43.9% | 57.3% | 77.8% | 48.2% | 52.1% | 47.8% | 52.7% |
| Operating margin | -104.5% | -332.4% | -94.7% | -100.2% | -222.4% | -24761.9% | -93.7% | -3576.8% |
| Net margin | -81.2% | -648.1% | -77.3% | -148.0% | -211.8% | -24356.2% | -94.8% | -3048.1% |
Company news
Jul 1, 2026
May 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-08-15 | Jolly Mohanjit | Award | 454,456 | — | — | filing |
| 2025-08-15 | Nelabhotla Venkateswarlu· President and CEO | Award | 7 | — | — | filing |
| 2025-08-15 | Dickey Robert IV· Chief Financial Officer | Award | 762 | — | — | filing |
Latest 3 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.